This is multi-institutional retrospective study in order to identify the most relevant clinical characteristics, treatment strategies, to explore the impact on principal clinical outcomes and finally, to suggest some principles for management and treatment of breast sarcomas. The study will collect data about patients affected by breast sarcoma referred to participating Institutions between January 2000 and June 2020
In the field of soft tissue sarcomas, breast sarcomas are a truly peculiar family of rare tumors for both their clinical history and biology of disease. Surgery (if feasible) is the main therapeutic approach for all the patients with localized disease, while a pharmacological (chemotherapeutic) and/or radiotherapeutic treatment is reserved to those with high-risk/recurrent-relapsing/metastatic disease. Unfortunately, there is a lack of specific prospective trials in breast sarcoma to guide the clinical decision-making and breast sarcoma patients are often sent to sarcoma referral centers only after surgery Due to sarcoma-specific clinical features, it is clear that both diagnostic and clinical strategies mandate a different approach compared to epithelial tumors. This is of key importance to reach the correct diagnosis, design the best therapeutic decision-making and subsequent follow-up. Even if retrospective data limitations and biases, in the lack of prospective data collection, these data may be a unique and precious source of information For this reasons this multi-institutional retrospective study is aimed to identify the most relevant clinical characteristics, treatment strategies, to explore the impact on principal clinical outcomes and finally, to suggest some principles for management and treatment of breast sarcomas.
Study Type
OBSERVATIONAL
Enrollment
300
This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments Reorder Outcome Measures
Azienda Ospedaliera S. Orsola-Malpighi
Bologna, BO, Italy
NOT_YET_RECRUITINGIstituto Europeo di Oncologia
Milan, MI, Italy
Treatments received for breast sarcoma
To describe treatment that patient diagnosed with breast sarcoma, received
Time frame: At diagnosis (baseline) and after 6, 12, 18, 24, 36, 48 and 60 weeks
Number of patients with primary breast sarcoma
Number of patient with a diagnosis of primary breast sarcoma
Time frame: Through study inclusion period, an average of 20 years
Number of patients with primary breast sarcoma symptoms
Number of patients with primary breast sarcoma symptoms
Time frame: Through study inclusion period, an average of 20 years
Local-regional Relapse Free Survival (LRFS)
Time elapsed form the treatment (any) start and the onset of Local-regional relapse
Time frame: Every 3 months (Month 3, Month 6, Month 9...) up to 5 years
Progression Free Survival (PFS)
Time elapsed form the treatment (any) start and the onset of progression
Time frame: Every 3 months (Month 3, Month 6, Month 9...) up to 5 years
Overall Survival (OS)
Time elapsed for the diagnosis to the death for any cause
Time frame: at 5 years
Median time of secondary breast sarcoma presentation
To define the median time to secondary sarcoma presentation
Time frame: Up to 3 years
Impact of upfront multidisciplinary tumor board consultation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Istituto Clinico Humanitas
Rozzano, MI, Italy
NOT_YET_RECRUITINGAzienda Ospedaliera Universitaria Paolo Giaccone
Palermo, PA, Italy
NOT_YET_RECRUITINGCentro di Riferimento Oncologico - Unit of Medical Oncology
Aviano, Pordenone, Italy
NOT_YET_RECRUITINGOspedale Misericordia e Dolce
Prato, PO, Italy
NOT_YET_RECRUITINGPoliclinico Universitario Campus Biomedico
Roma, RM, Italy
NOT_YET_RECRUITINGFondazione del Piemonte per l'Oncologia IRCC Candiolo
Candiolo, Torino, Italy
RECRUITINGOspedale Umberto I
Turin, TO, Italy
NOT_YET_RECRUITINGA.O Ospedali Riuniti Marche Nord
Ancona, Italy
NOT_YET_RECRUITING...and 4 more locations
To describe the impact of upfront multidisciplinary tumor board consultation on outcomes
Time frame: Up to 3 years